TABLE 2.

Summary of SLC7A11 involvement in cancer tissues

Tissue	Type of cells	SLC7A11 inhibitors used	Patient data (IHC or K‐M plot)	Relationship to therapeutic resistance	References
Breast	Basal type of breast cancer	SASP	Yes	‐	[22]
Esophagus	Squamous cell carcinoma	SASP	‐	‐	[63]
Colon	Colorectal cancer	SASP	Yes	‐	[64]
Lung	Non–small‐cell lung cancer (NSCLC)	SASP	Yes	‐	[65]
	KRAS‐mutant lung adenocarcinoma	SASP	Yes	‐	[66]
	Small‐cell lung cancer	SASP	Yes	Yes	[67]
Prostate	Advanced prostate cancer	Erastine	Yes	Yes	[68]
Pancreas	Pancreatic ductal adenocarcinoma	Erastine	‐	‐	[69]
Liver	Hepatocellular carcinoma	SASP	Yes	‐	[70]
	Hepatocellular carcinoma	‐	Yes	‐	[71]
Head and Neck	Squamous cell carcinoma	SASP	Yes	‐	[72]
	Oral cavity squamous cell carcinoma	‐	Yes	‐	[73]
Brain	Glioblastoma	‐	‐		[74]
	Glucose‐depleted glioma cells	SASP	‐	‐	[75]
Blood	Multiple myeloma	‐	Yes	‐	[76]
	Lymphoma	SASP	‐	‐	[77]
Thyroid	Papillary thyroid carcinoma	‐	Yes	‐	[53]